HC Wainwright Reiterates Buy Rating for Telix Pharmaceuticals (NASDAQ:TLX)

by · The Markets Daily

Telix Pharmaceuticals (NASDAQ:TLX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 74.98% from the company’s previous close.

Several other analysts have also recently issued reports on TLX. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Finally, Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $20.50.

Check Out Our Latest Research Report on Telix Pharmaceuticals

Telix Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:TLX traded up $0.12 during midday trading on Friday, reaching $11.43. 173,261 shares of the company traded hands, compared to its average volume of 220,486. The firm’s fifty day moving average price is $11.33 and its two-hundred day moving average price is $10.47. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $13.11.

Institutional Trading of Telix Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in TLX. Bank of America Corp DE lifted its holdings in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the last quarter. XY Capital Ltd bought a new position in Telix Pharmaceuticals in the first quarter valued at $120,000. Hennion & Walsh Asset Management Inc. purchased a new stake in Telix Pharmaceuticals during the second quarter valued at about $1,731,000. Private Advisor Group LLC raised its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its stake in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares during the last quarter.

Telix Pharmaceuticals Company Profile

(Get Free Report)

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.

Featured Articles